Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
KZKazia Therapeutics Ltd ADR logo

Kazia Therapeutics Ltd ADR (KZIA)

NASDAQ · Currency in USD
$7.81 ▼ -0.26 (-3.22%)
At close: Oct 23, 4:00 PM ET. Market closed.
$7.81 ▲ +0.00 (+0.00%)
After hours: Oct 23, 7:30 PM ET

Summary

Previous Close
$8.07
Open
$7.98
Day's Range
$7.48 – $8.06
52 Week Range
$4.86 – $17.40
Volume
52,674
Avg. Volume
244,956
Market Cap
$12.65M
Beta (5Y Monthly)
2.27
PE Ratio (TTM)
--
EPS (TTM)
-$7.14
Earnings Date
Mar 2, 2027
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$33.67

Profile: Kazia Therapeutics Ltd ADR

Sector
Healthcare
Industry
Biotechnology
Full-time employees
6
CEO
John Friend

Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3 that is in Phase I clinical trial to treat advanced solid tumors and ovarian cancer.

Earnings

Next report: Tue, Mar 2, 2027
EPS estimate -$0.10 · Revenue est. $1.96M
DateEst.Actual
Sep 4, 2026-$0.61-$0.46Beat
Mar 16, 2026-$0.01-$0.58Miss
Nov 7, 2025-$0.01-$0.43Miss
Jun 10, 2025-$10.76-$3.81Beat
Feb 20, 2025-$15.00-$20.80Miss
Sep 16, 2024-$3.00-$0.30Beat

Analyst view

Consensus price target
$33.67 ▲ +331.1%
Range $29.00 – $40.00
Rating: Buy
Buy 100% · Hold 0% · Sell 0%

Get free alerts on KZIA and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.